title: The Quit Experience and Concerns of Smokers With Psychiatric Illness.
abstract: The purpose of this study is to better understand the quit experience and concerns of smokers with psychiatric illness (i.e., major depressive, anxiety, psychotic and bipolar disorders) in comparison with those without psychiatric illness.
  
  
  
  Smokers (N=732) with (n=430, 59%) and without psychiatric illness, recruited between June 2010 and March 2013 to participate in the FLEX (Flexible and Extended Dosing of Nicotine Replacement Therapy [NRT] and Varenicline in Comparison to Fixed-Dose NRT for Smoking Cessation) smoking-cessation trial, completed questionnaires assessing previously used cessation aids and reasons for relapse, and motivation and concerns about their upcoming quit attempt. These supplementary data analyses were conducted in May 2015.
  
  
  
  The most commonly used cessation methods during previous attempts were nicotine replacement therapy (66.4%), cold turkey (59.7%), and bupropion (34.7%); no group differences were identified. Stress was the most common precipitator of relapse during previous attempts in all groups (43.6%), particularly among participants with depression and anxiety. Health was the most common motivation for the upcoming quit attempt (91%), followed by family/social pressures (28.1%) and cost (27.9%, particularly by smokers with psychotic disorders). Common pre-cessation concerns for the complete sample included: cravings (27.6%), stress (26.7%), and fear of failure (26%); participants with psychotic and anxiety disorders were most concerned about cravings, whereas the latter two concerns were more prominent for individuals with anxiety.
  
  
  
  Findings reveal differences in the quit histories and concerns of smokers with or without psychiatric illness. Smokers with psychiatric illness are particularly vulnerable to relapse at times of stress and negative affect; interventions that emphasize alternative coping strategies and facilitate mood management are required.
authors.affiliation: Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada;. Electronic address: hetulloch@ottawaheart.ca.
authors.forename: Heather E
authors.initials: HE
authors.lastname: Tulloch
authors.affiliation: Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Pipe
authors.affiliation: Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Clyde
authors.affiliation: Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Reid
authors.affiliation: Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Charl
authors.initials: C
authors.lastname: Els
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000523:psychology / Q000628:therapy*; D009042:Motivation; D018722:Nicotinic Agonists / Q000008:administration & dosage; D012907:Smoking / Q000523:psychology*; D016540:Smoking Cessation / Q000379:methods*; D011795:Surveys and Questionnaires; D061485:Tobacco Use Cessation Devices / Q000706:statistics & numerical data*; D000068580:Varenicline / Q000008:administration & dosage
chemical_list: D018722:Nicotinic Agonists; D000068580:Varenicline